Cite
Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome.
MLA
Li, Qianqian, et al. “Oral IRAK4 Inhibitor BAY-1834845 Prevents Acute Respiratory Distress Syndrome.” Biomedicine & Pharmacotherapy, vol. 153, Sept. 2022, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.biopha.2022.113459.
APA
Li, Q., Li, R., Yin, H., Wang, S., Liu, B., Li, J., Zhou, M., Yan, Q., & Lu, L. (2022). Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome. Biomedicine & Pharmacotherapy, 153, N.PAG. https://doi.org/10.1016/j.biopha.2022.113459
Chicago
Li, Qianqian, Rui Li, Hanlin Yin, Suli Wang, Bei Liu, Jun Li, Mi Zhou, Qingran Yan, and Liangjing Lu. 2022. “Oral IRAK4 Inhibitor BAY-1834845 Prevents Acute Respiratory Distress Syndrome.” Biomedicine & Pharmacotherapy 153 (September): N.PAG. doi:10.1016/j.biopha.2022.113459.